Clinical trials: Tamoxifen
Prostate Cancer, Osteoporosis
Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
Androgen deprivation therapy (ADT) treatment for prostate cancer decreases the natural hormone called testosterone. This type of therapy is very effective for the treatment of prostate cancer.
- Conditions
- Prostate Cancer, Osteoporosis, Fractures
- Trial name
- NCT00129142
- Testing
- Toremifene Citrate
- Where
- 155 sites in United States, Mexico
- Volunteers
- 1,200 people
- Sponsor
- GTx
Breast Cancer
SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer
RATIONALE: SU5416 may stop the growth of breast cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00005822
- Testing
- doxorubicin hydrochloride, semaxanib, conventional surgery
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer
Pilot Study About Tamoxifen Therapy for Breast Cancer Patients
The aim of this study are to to evaluate the knowledge and understanding on tamoxifen theraphy for breast cancer patients and examine the decision conflict scale and satisfaction with decision scale while making decision to take…
- Trial name
- NCT02094495
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- National Cancer Center, Korea
Breast Cancer Metastatic
Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer
Background: Endocrine therapy is an effective and safe treatment for hormone receptor positive breast cancer. Unfortunately , endocrine treatment resistance occurs and there is an urgent need for treatment alternative.
- Trial name
- NCT03045653
- Testing
- Tamoxifen Oral Product
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Comparison of Four Different Treatment Regimens in Treating Women With Stage I Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Estrogen can stimulate the growth of breast cancer cells.
- Trial name
- NCT00006030
- Testing
- tamoxifen citrate, conventional surgery, radiation therapy
- Where
- United Kingdom
- Sponsor
- British Association of Surgical Oncology: Breast Group
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
This randomized phase III clinical trial studies how well tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy work in treating patients with breast cancer that has spread from where it began in…
- Conditions
- Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma
- Trial name
- NCT01272037
- Testing
- Anastrozole, Exemestane, Laboratory Biomarker Analysis
- Where
- 1,568 sites in United States, Canada and 8 more
- Volunteers
- 5,018 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B Cell Lymphoma
Maintenance Hormonal Therapy and DLBCL
the study aims to detect the benefit of maintenance tamoxifen after achieving CR with conventional immuno-chemotherapy and/or radiotherapy in patients with DLDCL
- Trial name
- NCT06355401
- Testing
- Tamoxifen 20mg
- Volunteers
- 100 people
- Sponsor
- Sohag University
Breast Cancer
Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen.
- Trial name
- BIG 1-98 (NCT00004205)
- Testing
- letrozole, tamoxifen citrate
- Where
- 3 sites in Denmark, France and 1 more
- Volunteers
- 8,028 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
This research study is evaluating a drug called Palbociclib in combination with endocrine therapy as a possible treatment for hormone receptor positive breast cancer. Palbociclib is a drug that may stop cancer cells from growing.
- Trial name
- NCT02040857
- Testing
- Palbociclib, Aromatase Inhibitor
- Where
- 10 sites in United States
- Volunteers
- 162 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, HER2-positive
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
This is a Phase 2, single-site, single-arm open-label trial of zanidatamab in patients with early stage, low risk HER2+ BC. The primary objective is to determine the efficacy of zanidatamab for patients with early stage HER2/neu…
- Trial name
- NCT05035836
- Testing
- Zanidatamab, Letrozole, Tamoxifen
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
HER2-positive Breast Cancer, Breast Cancer
A Study of Skipping Radiation Therapy in People With Breast Cancer
The purpose of this study is to find out whether it is safe to skip (omit) radiation therapy to the breast after lumpectomy in people with low-risk HER2-positive breast cancer who are receiving HER2-targeted therapy.
- Trial name
- SuperHERO (NCT07895511)
- Testing
- HER2-targeted therapy, Tamoxifen, No Radiation Therapy
- Where
- 7 sites in United States
- Volunteers
- 136 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Osteoporosis, Postmenopausal
Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis
The purpose of this study is to determine whether the increase in spine bone mineral density that has been generally observed in previous clinical studies involving the study drug can be maintained or even increased if followed…
- Trial name
- NCT00035256
- Testing
- teriparatide, raloxifene HCl
- Where
- 5 sites in United States, Canada
- Volunteers
- 330 people
- Sponsor
- Eli Lilly and Company
Breast Cancer Patients in Premenopausal, Estrogen and/or Progesterone Receptor Positive
Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients
In premenopausal women, endocrine adjuvant therapy for breast cancer primarily consists of tamoxifen alone or with ovarian suppressive strategies.
- Trial name
- NCT02132000
- Testing
- toremifene or tamoxifen
- Where
- China
- Volunteers
- 3,036 people
- Sponsor
- Fengxi Su
Advanced Breast Cancer
Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)
CDK4/6 inhibitors are currently the standard treatment for female breast cancer patients with HR+ tumors. However, there is no established standard treatment for patients who experience treatment failure with CDK4/6 inhibitors.
- Trial name
- NCT05861830
- Testing
- The combination of Dalpiciclib with physician-selected endocrine therapy, Chemotherapy selected by the physician
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer
Tamoxifen-MRI Study
The project is a double blind, randomized, placebo-controlled phase II chemoprevention trial. Study participants will be randomly assigned to receive either tamoxifen or placebo for one year.
- Trial name
- NCT00295100
- Testing
- Tamoxifen
- Where
- 7 sites in United States, Italy
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Metastatic Breast Cancer
Roll-over Study to Allow Continued Access to Ribociclib
The purpose of this study is to assess the long-term safety of ribociclib (LEE011) in combination with other drugs and provide post-trial access (PTA) to participants who are currently receiving treatment with ribociclib in…
- Trial name
- NCT05161195
- Testing
- Ribociclib, Letrozole, Anastrozole
- Where
- 73 sites in United States, Argentina and 20 more
- Volunteers
- 134 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.
The purpose of the study is to to compare low dose of exemestane (babyexe) versus low dose of tamoxifen (babytam) in terms of change of quality of life from baseline to 12 months.
- Trial name
- BabyTears (NCT06364267)
- Testing
- Tamoxifen 10 MG, Exemestane 25 MG
- Where
- Italy
- Volunteers
- 140 people
- Sponsor
- Andrea DeCensi
Ovarian Carcinoma
REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression
The objective of this randomized phase II is to evaluate the benefit of regorafenib for ovarian patients who reported a confirmed elevated CA-125 level under surveillance or bevacizumab, compared with tamoxifen.
- Trial name
- REGOVAR (NCT02584465)
- Testing
- Tamoxifen, Regorafenib
- Where
- 21 sites in France
- Volunteers
- 68 people
- Sponsor
- ARCAGY/ GINECO GROUP
Breast Cancer
Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer
To investigate prospectively whether short term endocrine treatment can induce molecular changes, predictive for therapy response.
- Trial name
- NCT00738777
- Testing
- Anastrozole, Anastrozole+Fulvestrant, Tamoxifen
- Where
- 4 sites in Netherlands
- Volunteers
- 250 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer Stage IV
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
A assessment of the efficacy of first-/second-line endocrine therapies ± target therapies and chemotherapy in real-life of in patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer has not yet been…
- Trial name
- NCT04852081
- Testing
- Palbociclib, Ribociclib, Abemaciclib
- Where
- Russia
- Volunteers
- 1,000 people
- Sponsor
- Blokhin's Russian Cancer Research Center